Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life

Completed

Conditions: Parkinson Disease

First Posted Date: 2010-04-08

Last Posted Date: 2014-04-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1703

Registration Number: NCT01100073

Locations: 🇷🇴
Boehringer Ingelheim Investigational Site 89, Focsani, Romania
🇷🇴
Boehringer Ingelheim Investigational Site 102, Pascani, Romania
🇷🇴
Boehringer Ingelheim Investigational Site 117, Teleorman, Romania

and more 212 locations

Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease

Completed

Conditions: Parkinson Disease

Interventions: Drug: Pramipexole Extended Release

First Posted Date: 2010-04-01

Last Posted Date: 2014-04-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 329

Registration Number: NCT01097421

BI 671800 ED in Steroid-naive Asthmatic Patients

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: BI 671800
Drug: Fluticasone propionate
Drug: Fluticasone propionate placebo
Drug: BI 671800 Placebo

First Posted Date: 2010-03-24

Last Posted Date: 2022-05-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 389

Registration Number: NCT01092143

Locations: 🇨🇦
1268.17.02003 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
🇺🇸
1268.17.01034 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
🇺🇸
1268.17.01027 Boehringer Ingelheim Investigational Site, Novi, Michigan, United States

and more 89 locations

Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: BI 671800
Drug: Placebo

First Posted Date: 2010-03-19

Last Posted Date: 2022-05-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 108

Registration Number: NCT01090024

Locations: 🇺🇸
1268.53.01013 Boehringer Ingelheim Investigational Site, Huntington Beach, California, United States
🇺🇸
1268.53.01014 Boehringer Ingelheim Investigational Site, Mission Viejo, California, United States
🇺🇸
1268.53.01001 Boehringer Ingelheim Investigational Site, North Dartmouth, Massachusetts, United States

and more 11 locations

Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Cetuximab
Drug: BIBW 2992

First Posted Date: 2010-03-19

Last Posted Date: 2015-10-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 171

Registration Number: NCT01090011

Locations: 🇺🇸
1200.71.1001 Boehringer Ingelheim Investigational Site, New York, New York, United States
🇺🇸
1200.71.1004 Boehringer Ingelheim Investigational Site, Aurora, Colorado, United States
🇳🇱
1200.71.2002 Boehringer Ingelheim Investigational Site, Amsterdam, Netherlands

and more 3 locations

Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Glimepiride
Drug: Linagliptin

First Posted Date: 2010-03-16

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 241

Registration Number: NCT01087502

Locations: 🇦🇺
1218.64.61002 Boehringer Ingelheim Investigational Site, St Leonards, New South Wales, Australia
🇨🇦
1218.64.20007 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada
🇨🇦
1218.64.20008 Boehringer Ingelheim Investigational Site, Corunna, Ontario, Canada

and more 49 locations

LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Phase 3

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Investigator´s choice of chemotherapy
Drug: BIBW 2992

First Posted Date: 2010-03-11

Last Posted Date: 2017-04-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1154

Registration Number: NCT01085136

Locations: 🇬🇧
Boehringer Ingelheim Investigational Site, Truro, Cornwall, United Kingdom

Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: linagliptin

First Posted Date: 2010-03-10

Last Posted Date: 2014-01-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 241

Registration Number: NCT01084005

Locations: 🇩🇰
1218.63.45007 Boehringer Ingelheim Investigational Site, Aalborg, Denmark
🇩🇰
1218.63.45003 Boehringer Ingelheim Investigational Site, Aarhus C, Denmark
🇩🇰
1218.63.45001 Boehringer Ingelheim Investigational Site, Birkerød, Denmark

and more 31 locations

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Phase 2

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: dabigatran etexilate

First Posted Date: 2010-03-10

Last Posted Date: 2016-12-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT01083732

Locations: 🇹🇭
Boehringer Ingelheim Investigational Site, Khon Kaen, Thailand

Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium
Drug: Placebo

First Posted Date: 2010-02-22

Last Posted Date: 2013-12-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 126

Registration Number: NCT01072396

Locations: 🇺🇸
205.440.1002 Boehringer Ingelheim Investigational Site, Torrance, California, United States
🇺🇸
205.440.1018 Boehringer Ingelheim Investigational Site, Hartford, Connecticut, United States
🇺🇸
205.440.1015 Boehringer Ingelheim Investigational Site, Jasper, Alabama, United States

and more 12 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy